Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CMND Stock Alerts

Clearmind Medicine (CMND) Competitors

Clearmind Medicine logo
$1.86 +0.01 (+0.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.84 -0.02 (-0.81%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CMND vs. ADXN, CVKD, ACXP, ENVB, and GELS

Should you buy Clearmind Medicine stock or one of its competitors? Clearmind Medicine's main competitors and comparable companies include Addex Therapeutics (ADXN), Cadrenal Therapeutics (CVKD), Acurx Pharmaceuticals (ACXP), Enveric Biosciences (ENVB), and Gelteq (GELS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clearmind Medicine compare to Addex Therapeutics?

Clearmind Medicine (NASDAQ:CMND) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Clearmind Medicine has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Clearmind Medicine has higher earnings, but lower revenue than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$139.98N/A
Addex Therapeutics$210K32.13-$8.12M-$5.94N/A

In the previous week, Clearmind Medicine had 4 more articles in the media than Addex Therapeutics. MarketBeat recorded 6 mentions for Clearmind Medicine and 2 mentions for Addex Therapeutics. Clearmind Medicine's average media sentiment score of 1.07 beat Addex Therapeutics' score of 0.44 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Positive
Addex Therapeutics Neutral

Addex Therapeutics' return on equity of -134.76% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -143.79% -88.51%
Addex Therapeutics N/A -134.76%-106.00%

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Clearmind Medicine and Addex Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to Cadrenal Therapeutics?

Clearmind Medicine (NASDAQ:CMND) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 595.19%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Clearmind Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Clearmind Medicine had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 6 mentions for Clearmind Medicine and 4 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 1.09 beat Clearmind Medicine's score of 1.07 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearmind Medicine
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cadrenal Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Clearmind Medicine has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$139.98N/A
Cadrenal TherapeuticsN/AN/A-$13.24M-$5.63N/A

Clearmind Medicine's return on equity of -143.79% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -143.79% -88.51%
Cadrenal Therapeutics N/A -476.34%-307.13%

Summary

Cadrenal Therapeutics beats Clearmind Medicine on 7 of the 13 factors compared between the two stocks.

How does Clearmind Medicine compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 6 articles in the media. Clearmind Medicine's average media sentiment score of 1.07 beat Acurx Pharmaceuticals' score of -0.23 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Acurx Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Clearmind Medicine
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 2,122.22%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Clearmind Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acurx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/A
Clearmind MedicineN/AN/A-$3.86M-$139.98N/A

Acurx Pharmaceuticals' return on equity of -141.45% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Acurx PharmaceuticalsN/A -141.45% -96.50%
Clearmind Medicine N/A -143.79%-88.51%

Acurx Pharmaceuticals has a beta of -2.03, suggesting that its stock price is 303% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Acurx Pharmaceuticals and Clearmind Medicine tied by winning 6 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to Enveric Biosciences?

Clearmind Medicine (NASDAQ:CMND) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Clearmind Medicine had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 6 mentions for Clearmind Medicine and 3 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.89 beat Clearmind Medicine's score of 1.07 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearmind Medicine
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enveric Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Clearmind Medicine has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Clearmind Medicine's return on equity of -143.79% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -143.79% -88.51%
Enveric Biosciences N/A -220.97%-177.47%

Enveric Biosciences is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$139.98N/A
Enveric BiosciencesN/AN/A-$8.77M-$23.54N/A

Summary

Clearmind Medicine beats Enveric Biosciences on 6 of the 11 factors compared between the two stocks.

How does Clearmind Medicine compare to Gelteq?

Clearmind Medicine (NASDAQ:CMND) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Gelteq's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -143.79% -88.51%
Gelteq N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Gelteq
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Clearmind Medicine had 5 more articles in the media than Gelteq. MarketBeat recorded 6 mentions for Clearmind Medicine and 1 mentions for Gelteq. Gelteq's average media sentiment score of 1.87 beat Clearmind Medicine's score of 1.07 indicating that Gelteq is being referred to more favorably in the news media.

Company Overall Sentiment
Clearmind Medicine Positive
Gelteq Very Positive

96.1% of Clearmind Medicine shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Clearmind Medicine has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.45, suggesting that its stock price is 145% less volatile than the broader market.

Clearmind Medicine has higher earnings, but lower revenue than Gelteq.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$139.98N/A
Gelteq$110K56.47-$4.30MN/AN/A

Summary

Gelteq beats Clearmind Medicine on 5 of the 9 factors compared between the two stocks.

Get Clearmind Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMND vs. The Competition

Export
MetricClearmind MedicinePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.89M$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio-0.01640.15211.0921.74
Price / SalesN/A743.87602.9892.99
Price / CashN/A66.4570.4850.90
Price / Book0.1311.6012.916.24
Net Income-$3.86M$2.77B$3.45B$347.60M
7 Day Performance14.11%0.17%1.12%1.07%
1 Month Performance-3.63%0.35%1.79%1.03%
1 Year Performance-99.54%161.52%67.69%20.77%

Clearmind Medicine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMND
Clearmind Medicine
2.7418 of 5 stars		$1.86
+0.5%		N/A-99.5%$1.89MN/AN/AN/A
ADXN
Addex Therapeutics
0.2554 of 5 stars		$5.70
+0.2%		N/A-29.4%$7.02M$29.97KN/A30
CVKD
Cadrenal Therapeutics
2.4767 of 5 stars		$1.96
flat		$13.00
+563.3%		-84.1%$6.71MN/AN/A4
ACXP
Acurx Pharmaceuticals
2.4569 of 5 stars		$1.47
+2.8%		$31.00
+2,008.8%		-68.6%$6.32MN/AN/A3
ENVB
Enveric Biosciences
0.8911 of 5 stars		$1.69
+1.2%		N/A-88.7%$6.22MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMND) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel